Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
American Gene Technologies Celebrates Milestone in HIV Cure Development
On July 15, 2021, American Gene Technologies (AGT), a Maryland biotech company, announced that the safety data in its Phase
Continue Reading American Gene Technologies Celebrates Milestone in HIV Cure Development
Next Up for BioNTech: Malaria
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are
Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
A Framework for Protecting Your Invention Outside the U.S.
Patent protection outside the U.S. can be important for a company to enter the global market and to build relationships
Continue Reading A Framework for Protecting Your Invention Outside the U.S.
Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
Elizabeth Holmes, former CEO of the now-defunct blood-testing technology company Theranos, recently learned a harsh lesson on the complexities and
Continue Reading Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies